8-K: Aquestive Therapeutics Advances Anaphylm NDA Submission and Pipeline Development

Aquestive Therapeutics is progressing with its Anaphylm NDA submission, Libervant commercialization, and AQST-108 development, targeting significant market opportunities.

Summary

• Aquestive Therapeutics is focused on advancing medicines through innovative science and delivery technologies.
• The company's lead asset, Anaphylm (epinephrine) Sublingual Film, is in the process of NDA submission with the FDA, expected to be completed in March 2025.
• Anaphylm aims to be the first and only non-device based, orally delivered epinephrine product candidate.
• Clinical studies for Anaphylm have met predetermined primary and secondary endpoints, demonstrating bio-comparability to current standards of care.
• The U.S. market for epinephrine products is projected to reach ~$2B in value by 2031.
• Libervant (diazepam) Buccal Film has been launched for patients aged 2 to 5 years, with potential FDA approval for patients 6 to 11 years old expected.
• The company anticipates receiving full FDA approval for Libervant in January 2027 for patients 12 and up.
• AQST-108 (epinephrine) Topical Gel is being developed for alopecia areata, with a Phase 2a clinical study planned.
• Aquestive has end-to-end capabilities in research and development, manufacturing and packaging, and commercial activities.
• The company has over 150 employees and more than 2 billion PharmFilm doses shipped worldwide.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with advancements in the pipeline, clinical trial successes, and market opportunities. However, there are risks and challenges related to regulatory approvals, competition, and potential legal issues, which temper the overall sentiment.

Positives

• Anaphylm has the potential to transform the anaphylaxis market with its non-device based, orally delivered epinephrine.
• Clinical data supports Anaphylm's bio-comparability to current epinephrine auto-injectors.
• Libervant has already achieved FDA approval and launch for a specific patient population.
• AQST-108 targets a significant unmet need in alopecia areata treatment.
• Aquestive has strong end-to-end capabilities, including manufacturing and commercial expertise.
• The company has a dedicated and experienced leadership team.

Negatives

• Libervant's approval for patients aged 2 to 5 years is currently under appeal.
• The company faces orphan drug market exclusivity challenges for Libervant in older patient populations until January 2027.
• The success of Anaphylm and AQST-108 is contingent on FDA approval and market acceptance.

Risks

• Delays or changes in the timing, cost, and success of product development activities and clinical trials could impact the pipeline.
• The company may face challenges in generating sufficient clinical data for FDA approval of its product candidates.
• Competing products, including generics, could impact market share.
• Aquestive may not succeed in appealing the ruling regarding Libervant's approval for patients aged 2 to 5 years.
• Insufficient capital and cash resources could hinder commercialization and development activities.
• The company faces risks related to intellectual property rights and potential infringement claims.

Future Outlook

Aquestive anticipates launching Anaphylm in 2026, Libervant for ages 12 and up in 2027, and AQST-108 in 2028+, pending regulatory approvals and clinical endpoints.

Industry Context

Aquestive is operating in the pharmaceutical industry, specifically focusing on drug delivery technologies and addressing unmet needs in areas like anaphylaxis, epilepsy, and dermatological conditions. The company's focus on oral thin film technology positions it as a key player in this niche market.

Comparison to Industry Standards

• Aquestive's Anaphylm aims to compete with existing epinephrine auto-injectors (EAIs) like EpiPen and Auvi-Q, offering a needle-free alternative.
• The company's PharmFilm technology is used in Suboxone, a product of Indivior, demonstrating its established presence in the oral thin film market.
• AQST-108 is targeting the alopecia areata market, where JAK inhibitors are currently being explored, indicating a competitive landscape with potential for reasonable pricing.

Legal Proceedings

• The US District Court ruling against Libervant approval being appealed.

Stakeholder Impact

• Successful development and approval of Anaphylm could provide a more convenient and accessible treatment option for patients at risk of anaphylaxis.
• Expansion of Libervant's availability to older age groups could improve the management of acute repetitive seizures.
• AQST-108 could offer a new treatment option for patients with alopecia areata.
• The company's growth and success could benefit shareholders and employees.

Next Steps

• Complete the NDA submission for Anaphylm.
• Finalize the pediatric study for Anaphylm.
• Launch Anaphylm in 2026, pending FDA approval.
• Submit NDA and launch Libervant for ages 6 to 11, if approved by FDA.
• Launch Libervant for ages 12 and up in 2027.
• Commence Phase 2a clinical study for AQST-108.
• Launch AQST-108 in 2028+, pending FDA approval.

Key Dates